Printer Friendly

Neurelis Inc announces patent allowance in Japan for NRL-1 intranasal diazepam formulation for epilepsy patients.

M2 PHARMA-November 8, 2017-Neurelis Inc announces patent allowance in Japan for NRL-1 intranasal diazepam formulation for epilepsy patients

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Neurelis Inc reported on Tuesday the receipt of patent allowance from the Japan Patent Office (JPO) for its NRL-1 intranasal diazepam formulation for epilepsy patients who experience acute repetitive or cluster seizures.

The company's upcoming patent, which has been assigned the JP Application No. 2014-515967, is valid at least until 2032 upon issuance.

According to the company, NRL-1's formulation incorporates the unique combination of a Vitamin E-based solvent and Intravail absorption enhancement with the goal of obtaining unparalleled absorption, tolerability, and reliability in a nasal formulation. NRL-1 is in the final stage of clinical testing for its use in pediatric, adolescent, and adult epilepsy patients who experience acute repetitive or cluster seizures.

NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures,.

In addition, NRL-1 has been granted Orphan Drug and Fast Track Designations by the US FDA. In clinical trials, NRL-1 has demonstrated high bioavailability, low variability from dose to dose, and was well-tolerated - with reliable dosing, regardless of when administered. Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 8, 2017
Words:258
Previous Article:XVIVO Perfusion announces new reimbursement codes for US hospitals for doctors' time during EVLP procedures.
Next Article:ClearLight Diagnostics awarded exclusive intellectual property rights for its novel CLARITY-based tissue clearing instrumentation.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters